Breathe is a lung-support product sold through a lookalike swarm that attributes at least three different formulas to the name — a mullein-peppermint-ginger-lemon-manuka drop, a mullein-elderberry-quercetin blend, and an NAC-lobelia capsule — with no doses for any, a drops-versus-capsules format conflict, testimonials copy-pasted from an eye product ("Real VisiSharp Users"), and the flatly false claim of meeting FDA efficacy standards, which no dietary supplement does. Its marketing explicitly courts people with asthma, COPD and smoking histories — the audiences for whom delayed real treatment costs the most. Evidence rating: 1.5/5. Product Fit Score: 2.6/5. If the NAC version drew you in, NAC exists open-label at trial doses; if breathing is the problem, spirometry and inhaled therapy are the interventions with mortality evidence.
Breathe
- Form
- liquid drops
- Price
- $69 (1 bottle)
- Guarantee
- 90-day money-back (stated by seller)
- Sold via
- maxweb
- Label amounts
- UNRESOLVABLE VERSIONS — at least three ingredient rosters attributed across the swarm and a drops-vs-capsules format conflict; guarantee 90 days dominant with a 180 outlier; one page's testimonial block is headed 'Real VisiSharp Users' (an eye product); pages claim the product 'meets FDA efficacy standards' (false for any supplement); marketing explicitly targets asthma, COPD and smokers
✓ 90-day refund window stated by seller — long enough to run an honest self-trial
Check current price on the seller's site
Affiliate link. Prices and guarantee as shown on the seller's page on 3 September 2026; they may have changed. Not independently verified beyond that page.
Evidence & product fit
| Product Fit factor | Score (out of 5) | Why |
|---|---|---|
| Formula completeness | 1.0 | A swarm that can't agree on formula or format, testimonials headed "Real VisiSharp Users" (an eye product), a claim that the product "meets the stringent safety and efficacy standards set by the FDA" — false for every supplement that exists — and a 90-vs-180-day guarantee split. |
| Ease of use | 3.5 | The reported product format is inconsistent across seller/network pages, which reduces practical usability and confidence in what the buyer receives. |
| Guarantee & buying terms | 3.5 | 90 days dominant with mechanics described; one page says 180 — screenshot yours. |
| Price / value | 1.5 | ~$69 for a formula lottery. |
| Category relevance | 3.5 | Parts of the named formula are aligned with respiratory support positioning. Category relevance measures fit to the intended use; it does not mean the finished product has been clinically proven effective. |
Might suit you if…
- No constructible buyer — when the formula you'd receive is a three-way lottery and the seller's flagship compliance claim is false, there is no version of this purchase to recommend
Skip it if…
- Anyone with asthma or COPD — precisely the audience the ads name, and precisely who inhaled therapy (with real exacerbation-and-mortality evidence) exists for
- Ex-smokers buying a "lung detox" — lungs clear via cessation and time; the post-smoking screening that matters is a doctor conversation, not drops
- Anyone drawn by the NAC mention — real mucolytic, real doses (600–1,200 mg in studies), available open-label for a fraction of this price
The Evidence Rating reflects research on the finished product and/or named ingredients for the intended use. The Product Fit Score is a separate practical assessment of formula completeness, ease of use, guarantee/buying terms, price/value and category relevance. Neither score is a customer rating, and affiliate relationships do not determine either score. See the full scoring method.
What Breathe is
Breathe is a respiratory product sold through lookalike domains at ~$69/bottle with a 90-day guarantee (180 on one page) and a formula its own ecosystem tells three ways: herbal drops (mullein, peppermint, ginger, lemon peel, manuka honey), an elderberry-quercetin blend, or an NAC-lobelia capsule — no doses for any version, and a testimonial section on one page headed "Real VisiSharp Users" — an eye product's copy, incompletely swapped. Above it all sits the claim that Breathe "meets the stringent safety and efficacy standards set by the FDA" — a sentence that is false for every dietary supplement ever sold.
The audience is the finding
Our respiratory pair ends where Pulmo Balance began: the products are folklore, but the targeting is the harm. Breathe's pages name their buyers outright — asthma, COPD, chronic cough, smoking history — the exact populations for whom inhaled therapy carries mortality-grade evidence and for whom a season spent on mystery drops is the most expensive purchase in this entire queue, whatever the refund policy says. The one real compound in its rumor-cloud, NAC, is a legitimate dosed mucolytic sold openly — which is the polite version of this verdict.
| The ledger | |
|---|---|
| Formulas attributed | Three, incompatible |
| Format | Drops and capsules, by page |
| FDA efficacy claim | False, categorically |
| Testimonial integrity | Eye-product copy on a lung page |
| Guarantee | 90 dominant; 180 outlier |
Verdict
1.9/5 — a formula lottery wearing a false compliance badge, aimed at the readers with the most to lose. Respiratory symptoms that persist get spirometry; diagnosed airway disease gets inhalers with evidence; ex-smokers get time and screening; and the $69 stays home.
Frequently asked questions
Which Breathe formula would I actually get?
Unknowable from outside — the failure mode our NerveAlive and ProstaVive reviews named formula-by-fulfilment-lottery. Three rosters and two formats circulate on equally official-looking pages; no photographed panel settles it. Every downstream question (does it work, is it safe, what interacts) requires an answer to this one, and the seller hasn't provided it.
What's wrong with the FDA claim?
Everything. No dietary supplement "meets the stringent safety and efficacy standards set by the FDA" — supplements are legally exempt from pre-market efficacy review; that's the defining regulatory fact of the entire industry. A seller asserting FDA-verified efficacy is either ignorant of the category it operates in or counting on you being. Either reading grades every other claim on the page.
What should the targeted audiences actually do?
Asthma and COPD — controller inhalers and action plans, which carry the exacerbation and mortality evidence this aisle borrows language from; "going natural" off them is the category's costliest quiet harm. Ex-smokers — congratulations plus time (cilia recover over months), and a lung-cancer-screening conversation if you're 50+ with a significant pack-year history. Congestion and mucus — the one real molecule this swarm gestures at, NAC, exists dosed and cheap; ask your clinician if it fits.
Why is courting breathless buyers different from courting other supplement buyers?
Because breathlessness is medicine's tightest triage symptom — its differential (asthma, COPD, heart failure, clot, anemia, more) contains multiple entries where delay compounds damage or kills, and several where treatment transforms life within weeks. A funnel that aims 'lung support' copy at people describing wheeze and breathlessness is recruiting exactly the population with the least time to waste, which is why our review graded audience-targeting as a safety fact, not a marketing style. The category rule: any breathing symptom that is new, worsening, or limits activity has an evaluation pathway (spirometry is quick and cheap) that outranks every botanical ever sold — and a three-formula product under one name isn't ambiguity you can afford there.
Breathe — from $69 · 90-day seller refund window
Check current price on the seller's site Compare respiratory support supplements
Affiliate links. Our evaluation is unaffected — the criterion scores above explain the verdict either way.
References
- NHLBI. Sleep Apnea (2023). https://www.nhlbi.nih.gov/health/sleep-apnea
- NCCIH. Using Dietary Supplements Wisely (2019). https://www.nccih.nih.gov/health/using-dietary-supplements-wisely
- Federal Trade Commission. FTC Endorsement Guides (2023). https://www.ftc.gov/business-guidance/resources/ftcs-endorsement-guides-what-people-are-asking
Supplements do not treat asthma, COPD, pneumonia or another cause of shortness of breath. New or worsening breathing difficulty, chest pain, blue lips, confusion or low oxygen readings require prompt medical care. Do not stop inhalers or other prescribed respiratory medicines for a supplement.